U.S. markets close in 3 hours 34 minutes
  • S&P 500

    4,537.20
    +17.57 (+0.39%)
     
  • Dow 30

    35,642.85
    +185.54 (+0.52%)
     
  • Nasdaq

    15,140.52
    +11.43 (+0.08%)
     
  • Russell 2000

    2,293.71
    +17.80 (+0.78%)
     
  • Crude Oil

    83.77
    +0.81 (+0.98%)
     
  • Gold

    1,784.40
    +13.90 (+0.79%)
     
  • Silver

    24.41
    +0.52 (+2.19%)
     
  • EUR/USD

    1.1654
    +0.0016 (+0.14%)
     
  • 10-Yr Bond

    1.6390
    +0.0040 (+0.24%)
     
  • GBP/USD

    1.3821
    +0.0028 (+0.20%)
     
  • USD/JPY

    114.1800
    -0.1800 (-0.16%)
     
  • BTC-USD

    66,663.48
    +4,061.32 (+6.49%)
     
  • CMC Crypto 200

    1,552.64
    +71.83 (+4.85%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14, 2021 at 12:00 p.m. ET.

Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Ladenburg Thalmann conference coordinator. A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following the event for 60 days.

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contact
Peter Vozzo
Westwicke/ICR
Office: 443-213-0505
Cell: 443-377-4767
peter.vozzo@westwicke.com